Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741988 · ClinicalTrials.gov registry record · Phase 2
Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 13
- Study locations
NCT00741988 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by SCRI Development Innovations. The registered enrollment target is 82 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (88% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT00741988, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a multicenter, non-randomized, Phase II study of patients with previously untreated NSCLC not amenable to radiotherapy or surgical treatment. The planned enrollment for this trial is 78 patients (including a 10% rate for inevaluable patients). There will be a total of 39 patients in each cohort (Cohorts A and B).
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Ixabepilone
Study Locations (13)
Florida
- Florida Cancer Specialists - Fort Myers
- Gainsville Hematology Oncology Associates - Gainesville
South Carolina
- South Carolina Oncology Associates - Columbia
- Spartanburg Regional Medical Center - Spartanburg
Indiana
- Providence Medical Group - Terre Haute
Kentucky
- Consultants in Blood Disorders and Cancer - Louisville
Maryland
- Center for Cancer and Blood Disorders - Bethesda
Michigan
- Grand Rapids Clinical Oncology Program - Grand Rapids
Missouri
- Research Medical Center - Kansas City
Montana
- Dr. Donald Berdeaux - Great Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00741988
The ClinicalTrials.gov registry entry for NCT00741988 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (88% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00741988 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Florida, South Carolina, Indiana.
Frequently Asked Questions
What is clinical trial NCT00741988 about?
NCT00741988 is a clinical study titled "Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer". This is a multicenter, non-randomized, Phase II study of patients with previously untreated NSCLC not amenable to radiotherapy or surgical treatment. The planned enrollment for this trial is 78 patients (including a 10% rate for inevaluable patients). There will be a total of 39 patients in each coh...
What is the current status of trial NCT00741988?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2008-09. Estimated completion is 2012-09.
What conditions does trial NCT00741988 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00741988?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00741988?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00741988 being conducted?
This trial has 13 study locations across Florida, Indiana, Kentucky, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.